Hetrombopag Olamine

Phase 1/2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Severe Aplastic Anemia

Conditions

Severe Aplastic Anemia

Trial Timeline

Jun 20, 2018 → Jul 23, 2020

NCT ID

NCT03557099

About Hetrombopag Olamine

Hetrombopag Olamine is a phase 1/2 stage product being developed by Jiangsu Hengrui Medicine for Severe Aplastic Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03557099. Target conditions include Severe Aplastic Anemia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05944211	Phase 2	Recruiting	Jul 1, 2023	Jan 1, 2027	Chemotherapy-Induced Thrombocytopenia
NCT03977805	Phase 1	Completed	May 25, 2019	Jun 13, 2019	Healthy
NCT03603132	Phase 1	Completed	Jul 14, 2018	Aug 17, 2018	Immune Thrombocytopenia
NCT03557099	Phase 1/2	Completed	Jun 20, 2018	Jul 23, 2020	Severe Aplastic Anemia
NCT02614846	Phase 1	UNKNOWN	Aug 1, 2015	—	Chronic Idiopathic Thrombocytopenic Purpura
NCT02403440	Phase 1	UNKNOWN	Apr 1, 2014	—	Purpura, Thrombocytopenic, Idiopathic
NCT02409394	Phase 1	Completed	Mar 1, 2014	Apr 1, 2014	Healthy

Competing Products

20 competing products in Severe Aplastic Anemia

See all competitors

Product	Company	Stage	Hype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacaine	Pacira Biosciences	Approved	80
Drotrecogin alfa (activated)	Eli Lilly	Phase 2	52
CT-P13 SC Auto-Injector + Placebo Auto-Injector	Celltrion	Phase 3	77
CT-P17 + EU-approved Humira	Celltrion	Phase 3	77
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	77
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	77
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	77
CS-3150	Daiichi Sankyo	Phase 3	77
tacrolimus	Astellas Pharma	Approved	85
enzalutamide	Astellas Pharma	Phase 1	33
Isavuconazonium Injection [Cresemba] + Placebo	Astellas Pharma	Phase 3	77
Alefacept	Astellas Pharma	Approved	85
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)	Sun Pharmaceutical	Phase 2	52
Tildrakizumab 100 mg + Placebo	Sun Pharmaceutical	Phase 3	77
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + Placebo	Sun Pharmaceutical	Phase 2/3	65
Cefiderocol	Shionogi	Approved	85
eritoran tetrasodium + Placebo	Eisai	Phase 3	77
Donepezil HCl	Eisai	Approved	85
Donepezil Hydrochloride (Aricept)	Eisai	Approved	85
KHK4827 + Placebo	Kyowa Kirin	Phase 3	77

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved

Remimazolam TosilateApproved

Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved

ImrecoxibApproved

IvarmacitinibApproved